SCHEMBL22210591

SCHEMBL22210591

Cc1cc2[nH]c(C(C)C)nc2cc1C(F)(F)F

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.51
HSD17B10 Q99714 2/20 0.51
LMNA P02545 1/20 0.51
CACNA1H O95180 3/20 0.42
SCN10A Q9Y5Y9 2/20 0.41
HPGD P15428 3/20 0.40
ALDH1A1 P00352 2/20 0.40
NPSR1 Q6W5P4 1/20 0.40
MAPT P10636 3/20 0.40
POLB P06746 1/20 0.40
CYP1A2 P05177 1/20 0.39
FABP6 P51161 1/20 0.38
CACNA1G O43497 1/20 0.38
CACNA1C Q13936 1/20 0.38
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
ATM Q13315 2/20 0.37
CACNA1B Q00975 1/20 0.37
APBA1 Q02410 1/20 0.37
MCL1 Q07820 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11881600 0.89 KDM4E (0.56) KDM4EHSD17B10LMNACACNA1HSCN10A
SCHEMBL24312993 0.84 KDM4E (0.51) KDM4EHSD17B10LMNACACNA1HSCN10A
SCHEMBL19539999 0.83 KDM4E (0.50) KDM4EHSD17B10LMNACACNA1HSCN10A
SCHEMBL12724845 0.81 KDM4E (0.62) KDM4EHSD17B10LMNASCN10AHPGD
SCHEMBL12777696 0.81 KDM4E (0.51) KDM4EHSD17B10LMNACACNA1HSCN10A
SCHEMBL21983963 0.80 MAPT (0.60) KDM4EHSD17B10CACNA1HHPGDALDH1A1
SCHEMBL13542746 0.80 KDM4E (0.50) KDM4EHSD17B10LMNACACNA1HSCN10A
SCHEMBL5990707 0.79 KDM4E (0.56) KDM4EHSD17B10LMNASCN10AHPGD
SCHEMBL11875522 0.77 LMNA (0.44) KDM4EHSD17B10LMNACACNA1HSCN10A
SCHEMBL17300677 0.76 HSD17B10 (0.56) KDM4EHSD17B10LMNASCN10AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10711011-B2 Substituted oxazolidines as anti-bacterial agents Bugworks Research, Inc. (US) 2020-07-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10711011-B2 Substituted oxazolidines as anti-bacterial agents ALPI, HLA-A, HLA-B KDM4E 4214/4885HSD17B10 3332/4885LMNA 2797/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.